Novartis Australia, and its generics and biosimilars division Sandoz, has confirmed that it will be working with the Australian government to provide an initial supply of generic hydroxychloroquine to support the COVID-19 pandemic response.
Apr 02, 2020
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. The supply is part of a global commitment by Novartis to donate doses of hydroxychloroquine where it is supported by local regulatory authorities for use in COVID-19 infected patients.
For further information about what Novartis is doing globally, visit our global statement.